OCR strengthens its leadership position in cancer research thanks to the collaboration with Beta Innov, Atlanthera, and an industry leader in veterinary pharmaceuticals.

Clinical studies that will research glioblastoma (a quick and agressive malignant brain tumor) and bone cancer.